$0.61
+0.01 (+1.02%)
Open$0.65
Previous Close$0.61
Day High$0.65
Day Low$0.60
52W High$36.44
52W Low$21.58
Volume—
Avg Volume61.9K
Market Cap29.72M
P/E Ratio33.54
EPS$0.92
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+6,486.1% upside
Current
$0.61
$0.61
Target
$40.32
$40.32
$26.90
$40.32 avg
$53.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.14M | 4.74M | 5.21M |
| Net Income | 951.6K | 665.5K | 945.6K |
| Profit Margin | 18.5% | 14.0% | 18.1% |
| EBITDA | 1.31M | 1.24M | 1.40M |
| Free Cash Flow | 380.5K | 530.0K | 488.3K |
| Rev Growth | -9.9% | +8.5% | -0.4% |
| Debt/Equity | 0.11 | 0.10 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |